CPhI survey forecasts sustained pharma growth in India

New CPhI survey points to sustained pharma growth in India, with an improving outlook for finished dosage, API and biologics

Indicating a positive outlook, India-specific findings of the CPhI Annual Report survey conducted among 350 executives, showcases a sustained pharma growth in India, with an improving outlook for finished dosage, API and biologics.

The 14th Annual CPhI & P-MEC India will run in a hybrid form, with an online conference and networking from November 15-30 alongside an in-person event in New Delhi on November 24-26. The annual conference organised by Informa Markets – is set to welcome attendees and exhibitors from around the world, both online and in-person.

India’s single biggest metric improvement in the CPhI data was in the perceived quality of ‘finished dose manufacturing’, where the country surged 13 percent in year, adding to the four percent rise saw in 2020, while it also jointly topped the prestigious ‘growth potential’ category with the United States for the first time.

“There is a tremendous need for new manufacturing partners and as shown in the report – Indian manufacturers in particular are in high demand. By delivering a hybrid event and offering a platform where international and national buyers and suppliers can profile themselves, we are facilitating greater opportunity for future partnerships,” commented Silvia Forroova, Brand Director at Informa.

According to the survey, India saw its reputation for API manufacturing improve by seven percent year-on-year. Emphasising this shift in perspectives, in 2021 there has been a five-fold increase in private equity investments totalling $1.5 billion into API companies across the country.

In fact, to help attendees explore this burgeoning sector further, the second day of CPhI & P-MEC India’s online conference will feature a live panel discussion on API & Next Gen Labs. The session will offer foresight into the emerging possibilities for automation and robotics in pharmaceutical manufacturing as well as evaluating the complexity of the global API supply chain on November 16 – online .

In another boon to Indian manufacturing, the country showed the largest gains in terms of ‘growth potential for biologics manufacturing’ of any country – including traditional biologics powerhouses France, the USA, Singapore, and the UK – perhaps helped by the Serum Institute of India’s (SII) well documented supply of COVID vaccines.

Highlighting this issue’s current prominence in India, a panel of experts, moderated by Duncan Emerton, executive director, custom intelligence & analytics at Informa Pharma Intelligence, will explore the opportunities and challenges for biologics and biosimilars on November 17 online.

To enhance networking and deal-making at the event, the online event platform will open more than a week before the start of the in-person event, empowering the industry to maximise the value they get from the in-person CPhI & P-MEC India. This enables companies to identify more partners in advance and pre-qualify their leads.
The online platform will also play host to some 30 sessions spanning four tracks – Drug Development and Delivery, API & Next Gen Labs, Biosimilars & mAbs and Digitization. Running alongside the event is India Pharma week which will host the ‘Women in Pharma’ roundtable as well as the eighth annual India Pharma Awards.

Silvia Forroova, Brand Director at Informa, said, “With multitude of new opportunities emerging out of India, which is why we are really looking forward to hosting the hybrid CPhI & P-MEC India. With so many opportunities to network over the course of the fortnight, I would encourage everyone to take advantage of the online platform to not only set-up virtual meetings, but to also pre-qualify leads ahead of the in-person event.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here